CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Standard Ventilation StrategyWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug1781 Pectin Wiki 1.00
drug2080 Respiratory Mechanics Wiki 1.00
drug106 Acacia Senegal Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Careful Ventilation in COVID-19 -Induced Acute Respiratory Distress Syndrome

This is a multicenter randomized controlled clinical trial with adaptive design assessing the efficacy of setting the ventilator based on measurements of respiratory mechanics (recruitability and effort) to reduce Day 60 mortality in patients with acute respiratory distress syndrome (ARDS)

NCT03963622 ARDS Other: Respiratory Mechanics Other: Standard Ventilation Strategy
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury

Primary Outcomes

Description: The lack of an appropriate surrogate endpoint, and the high baseline mortality rate mandate a multicentre RCT to determine the mortality effects of setting the ventilator based on recruitability and effort compared with conventional ventilation.

Measure: All-cause 60-day mortality

Time: 60 days

Secondary Outcomes

Measure: Duration of ventilation

Time: Duration of ventilation in days, which may exceed 60 days

Measure: Duration of ICU and hospital stay

Time: Duration of ICU and hospital stay in days, which may exceed 60 days

Description: Organ dysfunction as per the SOFA score

Measure: Number of patients with organ dysfunction

Time: Day 1-7, 14, 21, 28

Description: Barotrauma defined as new onset of pneumothorax

Measure: Number of patients with barotrauma

Time: Up to 60 days

Measure: Mortality at ICU discharge, 28 days, and hospital discharge

Time: Up to date of ICU discharge, 28 days, and hospital discharge

Other Outcomes

Description: Biomarkers include interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor receptor 1 (TNFr1), soluble receptor of the advanced glycation end products (sRAGE), and surfactant protein D (SPD). All measured in pg/ml

Measure: The change in biomarker expression

Time: Baseline, 24 and 72 hours


No related HPO nodes (Using clinical trials)